The fact that animals receiving anti-NK1.1 therapy in addition to ACT experience vitiligo sooner than animals receiving ACT alone suggests that the adoptively transferred TRP-1-specific CD4+ T cells are rejecting TRP-1+ cells more quickly under these conditions. Here, CD4 is linked to vitiligo.